Diagnostic performance and prognostic value of extravascular retention of 123I-labeled serum amyloid P component in systemic amyloidosis

Journal of Nuclear Medicine

Volumn 48, Issue 6, 2007, Pages 865-872

  Hazenberg, Bouke P C ^a   Van Rijswijk, Martin H ^a   Lub de Hooge, Marjolijn N ^a   Vellenga, Edo ^a   Haagsma, Elizabeth B ^a   Posthumus, Marcel D ^a   Jager, Pieter L ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Diagnostic accuracy; Prognostic factor; Serum amyloid P component; Systemic amyloidosis

Indexed keywords

ALKALINE PHOSPHATASE; CREATININE; IODINE 123; SERUM AMYLOID P; SERUM AMYLOID P I 123; UNCLASSIFIED DRUG;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; AMYLOIDOSIS; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DIAGNOSTIC VALUE; DRUG DISTRIBUTION; DRUG RETENTION; DRUG UPTAKE; FEMALE; HEART; HUMAN; KIDNEY; LIVER; MAJOR CLINICAL STUDY; MALE; NERVE; PRIORITY JOURNAL; PROGNOSIS; SCINTIGRAPHY; SENSITIVITY AND SPECIFICITY; SURVIVAL; TISSUE DISTRIBUTION;

ADULT; AGED; AMYLOIDOSIS; FEMALE; HEART DISEASES; HUMANS; IODINE RADIOISOTOPES; KIDNEY DISEASES; LIVER DISEASES; MALE; MIDDLE AGED; PERIPHERAL NERVOUS SYSTEM DISEASES; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; SERUM AMYLOID P-COMPONENT; TISSUE DISTRIBUTION;

EID: 34250370799     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.106.039313     Document Type: Article

References (24)

1. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med. 1997;337:898-909.
2. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349:583-596.
3. Pepys MB, Booth DR, Hutchinson WL, Gallimore JR, Collins PM, Hohenester E. Amyloid P component: a critical review. Amyloid. 1997;4:274-295.
4. 123I-labeled serum amyloid P component. N Engl J Med. 1990;323:508-513.
5. Hawkins PN, Richardson S, MacSweeney JE, et al. Scintigraphic quantification and serial monitoring of human visceral amyloid deposits provide evidence for turnover and regression. Q J Med. 1993;86:365-374.
6. Hawkins PN, Richardson S, Vigushin DM, et al. Serum amyloid P component scintigraphy and turnover studies for diagnosis and quantitative monitoring of AA amyloidosis in juvenile rheumatoid arthritis. Arthritis Rheum. 1993;36:842-851.
7. Rydh A, Suhr O, Hietala S-O, Ahlstrom KR, Pepys MB, Hawkins PN. Serum amyloid P component scintigraphy in familial amyloid polyneuropathy: regression of visceral amyloid following liver transplantation. Eur J Nucl Med. 1998;25:709-713.
8. 123I serum amyloid P component scintigraphy in 484 patients. Gut. 1998;42:727-734.
9. Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet. 2001;358:24-29.
10. 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis. Am J Med. 2006;119:355.e15-e24.
11. Hawkins PN, Wootton R, Pepys MB. Metabolic studies of radioiodinated serum amyloid P component in normal subjects and patients with systemic amyloidosis. J Clin Invest. 1990;86:1862-1869.
12. Jager PL, Hazenberg BP, Franssen EJF, Limburg PC, van Rijswijk MH, Piers DA. Kinetic studies with iodine-123-labeled serum amyloid P component in patients with systemic AA and AL amyloidosis and assessment of clinical value. J Nucl Med. 1998;39:699-706.
13. Hawkins PN, Aprile C, Capri G, et al. Scintigraphic imaging and turnover studies with iodine-131 labelled serum amyloid P component in systemic amyloidosis. Eur J Nucl Med. 1998;25:701-708.
14. Hachulla E, Maulin L, Deveaux M, et al. Prospective and serial study of primary amyloidosis with serum amyloid P component scintigraphy: from diagnosis to prognosis. Am J Med. 1996;101:77-87.
15. Reyners AK, Hazenberg BP, Haagsma EB, Tio RA, Reitsma WD, Smit AJ. The assessment of autonomic function in patients with systemic amyloidosis: methodological considerations. Amyloid. 1998;5:193-199.
16. Pearson TC, Guthrie DL, Simpson J, et al. Interpretation of measured red cell mass and plasma volume in adults: Expert Panel on Radionuclides of the International Council for Standardization in Haematology. Br J Haematol. 1995;89:748-756.
17. Nadler SB, Hidalgo JU, Bloch T. Prediction of blood volume in normal human adults. Surgery. 1962;51:224-232.
18. Balga I, Solenthaler M, Furlan M. Should whole-body red cell mass be measured or calculated? Blood Cells Mol Dis. 2000;26:25-31.
19. Dispenzieri A, Gertz MA, Kyle RA, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2004;104:1881-1887.
20. Palladini G, Campana C, Klersy C, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation. 2003;107:2440-2445.
21. Lachmann HJ, Gallimore R, Gillmore J, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol. 2003;122:78-84.
22. Thompson D, Pepys MB, Tickle I, Wood S. The structures of crystalline complexes of human serum amyloid P component with its carbohydrate ligand, the cyclic pyruvate acetal of galactose. J Mol Biol. 2002;320:1081-1086.
23. 99mTc-MAMA-chrysamine G as an in vivo probe for amyloidosis. Amyloid. 2001;8:202-214.
24. Wall JS, Kennel SJ, Paulus M, et al. Radioimaging of light chain amyloid with a fibril-reactive monoclonal antibody. J Nucl Med. 2006;47:2016-2024.